Beyond Cancer Reports Phase 1a Data on Nitric Oxide Treatment for Solid Tumors at ASCO 2024

Beyond Cancer, Ltd., a clinical-stage biotechnology company developing ultra-high concentration nitric oxide (UNO) as an immunotherapeutic for solid tumors, announced encouraging first-in-class clinic

BenzingaJun 3 06:12

Beyond Cancer Presents First-in-Class Clinical Data Showing an Immunogenic Response in Subjects With R/r Unresectable Solid Tumors Treated With Ultra-High Concentration Nitric Oxide (UNO)

– Ongoing Phase 1a first-in-human clinical trial continues to demonstrate proof of concept for the UNO solid tumor platform with observed early tumor responses and clinical resolution of radiation dermatitis – Phase

GlobeNewswireJun 3 06:00

Beyond Air Up 11%, Insiders Still Down After US$3.05m Purchase

Yahoo FinanceMay 31 07:36

Beyond Air Schedules Fiscal Year End 2024 Financial Results Conference Call and Webcast

Conference call scheduled for Monday, June 24th at 4:30 pm ETGARDEN CITY, N.Y., May 23, 2024 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) ("Beyond Air" or the "Company"), a commercial stage m

GlobeNewswireMay 23 15:09

Beyond Air Price Target Cut to $8.00/Share From $10.00 by Truist Securities

Beyond Air Price Target Cut to $8.00/Share From $10.00 by Truist Securities

Dow JonesApr 30 12:16

Beyond Air Is Maintained at Buy by Truist Securities

Beyond Air Is Maintained at Buy by Truist Securities

Dow JonesApr 30 12:16